KRAS and lung cancer: Our research originally found downregulation of SDPR in lung cancers as well as in KRAS-mutant subgroup (Fig. 2a–g), and innovatively explored the immune checkpoint molecules and abundance of immune infiltrations at different SDPR expression and CNVs models (Fig. 6a–c, Table 2).